Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

PUBLISHED DATE : Oct 2021 | Pages : 210

Up to $525 off Until Aug 2022

THE GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE WAS VALUED AT USD 169.47 BILLION IN 2020 AND IS EXPECTED TO REACH USD 326.36 BILLION BY 2026, GROWING AT A CAGR OF 11.54%

The Immunotherapy Drugs Market Share, Size & Trends Analysis By Product (Monoclonal Antibodies, Immune System Modulators, Car T-Cell Therapies, and Others), By Application (Cancer, Auto-Immune & Inflammatory Disease, and Others), and By Geography (North America, Europe, APAC, Latin America, and the Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

210 Pages

icon-table

35 Tables

icon-chart

75 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

21 Companies

icon-market

3 Market Segment

IMMUNOTHERAPY DRUGS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 326.36 BILLION (2026)
CAGR 11.54% (2021-2026)
BASE YEAR 2020
FORECAST YEAR 2021-2026
MARKET SEGMENTS By Product (Monoclonal Antibodies, Immune System Modulators, Car T-Cell Therapies, and Others), By Application (Cancer, Auto Immune & Inflammatory Disease, and Others)
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, and Middle East & Africa
COUNTRIES COVERED US, Canada, Germany, UK, France, Italy, Spain, China, India, Japan, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, and Turkey

IMMUNOTHERAPY DRUGS MARKET OVERVIEW

The global immunotherapy drugs market size was valued at USD 169.47 billion in 2020 and is expected to reach USD 326.36 billion by 2026, growing at a CAGR of 11.54%. The major factor responsible for immunotherapy drugs market growth is an increase in demand for outsourcing the manufacturing of immunotherapy drugs by several biopharmaceuticals and biotechnological companies and resistance against conventional treatments. Major key players and other prominent vendors engaged in the immunotherapy drugs domain are constantly focussing on product launches, product approvals, R&D activities, and expanding their organic growth.

KEY HIGHLIGHTS

  • The emergence of various diseases in developing countries is propelling the usage of monoclonal antibodies, demanding the introduction of newer immunotherapies and creating opportunities for the market.
  • Cancer immunotherapy drugs revolutionized cancer therapies that have begun to shift the curve of cancer patients by increasing their lifespan.
  • The increasing immunotherapy drugs pipeline coupled with the emergence of the pandemic has scaled up the production of medicines.
  • By product, the adoptive cell therapy segment is expected to witness absolute growth of 1280% during the forecast period.
  • The recent immunotherapy drugs market trends of mergers and acquisitions are boosting the growth of the immunotherapy drugs industry. For instance, Bristol-Myers Squibb’s one of most recent and high-value transactions was the acquisition of Celgene in January 2018.

IMMUNOTHERAPY MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Product
  • Application
  • Geography

IMMUNOTHERAPY MARKET SEGMENTS

  • The monoclonal antibody segment accounted for the high share of 72.6% of the global immunotherapy drugs market share in 2020. Significant advances in the field, notably, and the unprecedented results obtained using monoclonal antibodies that attach themselves to lymphocytes. This restores their functioning toward tumor cell and thus create a defense for the body against cancer.
  • The autoimmune diseases segment accounted for the highest market share in 2020. It is expected to post an incremental growth of USD 23.95 billion with 33% absolute growth during the forecast period. The segment's growth is attributed to the increase in the prevalence of immune-mediated inflammatory diseases (IMIDs), including autoimmune and auto-inflammatory diseases.
  • In 2020, the cancer segment accounted for the highest market share of 45.33%. Immunotherapies in oncology have been widely popularized by developing curative therapies, such as CAR T-cell. However, developing personalized therapies such as CAR T-cell to treat various types of cancers may pose significant challenges, such as educating medical personnel regarding the procedures and creating a convenient process for engineering T-cells of the patients and infusing them.

GEOGRAPHICAL ANALYSIS

  • North America: North America has the highest share among all the regions and is likely to witness an absolute growth of around 105% during the forecast period. The rise in the immunotherapy drugs industry is primarily attributable to the increasing incidence rates of various types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, leukemia, etc.
  • Europe: Europeans represent about one-tenth of the global population, yet one in four of all cancer diagnoses occur in this region. This region is likely to witness an absolute growth of around 84% during the forecast period. 
  • APAC: APAC is witnessing growing demand mainly due to a large and growing population. In APAC, various opportunities associated with the growth of the cancer immunotherapy drugs market are increasing, and government initiatives will further improve the healthcare sector.

VENDOR ANALYSIS

  • The major vendors such as F. Hoffmann-La Roche, Bristol Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline, Novartis, AstraZeneca, and Janssen Pharmaceuticals Inc.
  • Bristol Myers Squibb (BMS) is a biopharmaceutical company that is helping – outpatients in succeeding aliments by delivering innovative products. It has owned innovative drugs such as OPDIVO Immunotherapy Drugs for a wider range of diseases.
  • Market competitiveness is expected to increase during the forecast period as the vendors constantly focus on expanding their product portfolios.
  • Most of the leading key players are focusing on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their presence in the global market.
  • Established players are entering into various strategic alliances and co-marketing agreements to elevate competitiveness and penetration.


The global immunotherapy drugs market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

By Product

  • Monoclonal Antibodies
  • Immune System Modulators
  • Car T-Cell Therapies
  • Others

By Application

  • Cancer
  • Auto Immune & Inflammatory Disease
  • Others

By Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

Frequently Asked Questions

How big is the immunotherapy drugs market?

The global immunotherapy drugs market was valued at USD 169.47 billion in 2020 and is projected to reach USD 326.36 billion by 2026.

What are the products segmentation in the immunotherapy drugs market?

The different product segmentation in the immunotherapy drugs market is monoclonal antibodies, immune system modulators, Car T-Cell therapies, and others.

Which region has the highest growth rate for the immunotherapy drugs industry?

North America is the region with the highest growth rate in the immunotherapy drugs industry.

What are the immunotherapy drugs market trends?

The latest trends in the global immunotherapy drugs industry are next-generation immunotherapies, the impact of COVID-19 as a catalyst, and investment in research & development activities.

What is the impact of COVID-19 on the immunotherapy drugs market?

COVID-19 was a catalyst for the immunotherapy drugs industry as COVID-19, and non-COVID-19 related drugs and treatments continue to be developed and witnessed high demand during the period.

Who are the prominent players in the global immunotherapy drugs market?

The key players in the global immunotherapy drugs industry are F. Hoffmann-La Roche, Bristol Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline, Novartis, AstraZeneca, and Janssen Pharmaceuticals Inc.

Which countries are the major contributor for Cancer Immunotherapy Drugs Market in APAC?

China and India are the major contributors in the Asia Pacific cancer immunotherapy market.

Download Free Sample

The global immunotherapy drugs market was valued at USD 169.47 billion in 2020 and is expected to reach USD 326.36 billion by 2026, growing at a CAGR of 11.54%.

The following factors are likely to contribute to the growth of the global immunotherapy market during the forecast period:

  • Next-generation immunotherapies
  • COVID-19 as a catalyst
  • Investment in research & development activities
  • Mergers & acquisitions
  • Surge of CAR-T therapies 

Base Year: 2020

Forecast Year: 2021-2026

The study considers a detailed scenario of the present global immunotherapy drugs market and its market dynamics for the period 2021−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Key Vendors

  • F. Hoffmann-La Roche
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Bristol Myers Squibb Company
  • Merck & Co., Inc.
  • GlaxoSmithKline
  • Novartis
  • AstraZeneca
  • Janssen Pharmaceuticals, Inc.

Other Prominent Vendors

  • AbbVie
    • Business Overview
    • Product Offerings
  • Alexion Pharmaceuticals
  • Amgen
  • Bayer
  • Dendreon
  • Dynavax
  • Eli Lilly and Company
  • Elusys Therapeutics, Inc
  • Gilead Sciences, Inc
  • NBE Therapeutics
  • Pfizer, Inc
  • Sanofi
  • Seagen Inc.
  • Teva pharmaceuticals

Segmentation by Product

  • Monoclonal Antibodies
  • Immune System Modulators
  • Car T-Cell Therapies
  • Others

Segmentation by Application

  • Cancer
  • Auto Immune & Inflammatory Disease
  • Others

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

 

1            Research Methodology

2            Research Objectives

3            Research Process

 

4            Scope & Coverage

4.1        Market Definition

4.1.1     Inclusions

4.1.2     Exclusions

4.1.3     Market Estimation Caveats

4.2        Base Year

4.3        Scope of the Study

4.3.1     Market Segmentation by Geography

4.3.2     Market Segmentation by Product

4.3.3     Market Segmentation by Application

 

5            Report Assumptions & Caveats

5.1        Key Caveats

5.2        Currency Conversion

5.3        Market Derivation

 

6            Market at a Glance

 

7            Introduction

7.1        Overview

 

8            Market Opportunities & Trends

8.1        Launch of Next-Generation Immunotherapies

8.2        COVID-19 as Growth Catalyst

8.3        Investment in R&D Activities

8.4        Mergers & Acquisitions

 

9            Market Growth Enablers

9.1        Prevalence of Cancer & Autoimmune Diseases

9.2        Approval of Novel Immunotherapy Drugs

9.3        Surge in Adoption of Car T-Cell Therapies

 

10         Market Restraints

10.1      Expensive Nature of Immunotherapy

10.2      Personalized Approach Through Biomarkers

10.3      Time-Consuming Production Cycle

 

11         Market Landscape

11.1      Market Overview

11.2      Market Size & Forecast

11.2.1   Geographic Insights

11.2.2   Application Insights

11.2.3   Product Insights

11.3      Impact of COVID-19 on Immunotherapy Drugs

11.4      Porter’s Five Forces Analysis

11.4.1   Threat of New Entrants

11.4.2   Bargaining Power of Suppliers

11.4.3   Bargaining Power of Buyers

11.4.4   Threat of Substitutes

11.4.5   Competitive Rivalry

 

12         Product

12.1      Market Snapshot & Growth Engine

12.2      Market Overview

12.3      Monoclonal Antibody

12.3.1   Market Overview

12.3.2   Market Size & Forecast

12.4      Immune System Modulators

12.4.1   Market Overview

12.4.2   Market Size & Forecast

12.5      Car T-Cell Therapy

12.5.1   Market overview

12.5.2   Market Size & Forecast

12.6      Others

12.6.1   Market overview

12.6.2   Market Size & Forecast

 

13         Application

13.1      Market Snapshot & Growth Engine

13.2      Market Overview

13.3      Cancer

13.3.1   Market overview

13.3.2   Market Size & Forecast

13.4      Autoimmune & Inflammatory Diseases

13.4.1   Market overview

13.4.2   Market Size & Forecast

13.5      Others

13.5.1   Market overview

13.5.2   Market Size & Forecast

 

14         Geography

14.1      Market Snapshot & Growth Engine

14.2      Geographic Overview

 

15         North America

15.1      Market Overview

15.2      Market Size & Forecast

15.3      Key Countries

15.3.1   US: Market Size & Forecast

15.3.2   Canada: Market Size & Forecast

 

16         Europe

16.1      Market Overview

16.2      Market Size & Forecast

16.3      Key Countries

16.3.1   Germany: Market Size & Forecast

16.3.2   UK: Market Size & Forecast

16.3.3   France:  Market Size & Forecast

16.3.4   Italy: Market Size & Forecast

16.3.5   Spain: Market Size & Forecast

 

17         Asia Pacific

17.1      Market Overview

17.2      Market Size & Forecast

17.3      Key Countries

17.3.1   China: Market Size & Forecast

17.3.2   India: Market Size & Forecast

17.3.3   Japan: Market Size & Forecast

17.3.4   Australia: Market Size & Forecast

17.3.5   South Korea: Market Size & Forecast

 

18         Latin America

18.1      Market Overview

18.2      Market Size & Forecast

18.3      Key Countries

18.3.1   Brazil: Market Size & Forecast

18.3.2   Mexico: Market Size & Forecast

18.3.3   Argentina: Market Size & Forecast

 

19         Middle East & Africa

19.1      Market Overview

19.2      Market Size & Forecast

19.3      Key Countries

19.3.1   South Africa: Market Size & Forecast

19.3.2   Saudi Arabia: Market Size & Forecast

19.3.3   Turkey: Market & Forecast

 

20         Competitive Landscape

20.1      Competition Overview

20.2      Market Share Analysis

20.2.1   F. Hoffmann-La Roche AG

20.2.2   Bristol Myers Squibb

20.2.3   Merck & Co., Inc.

20.2.4   GlaxoSmithKline

20.2.5   Novartis

20.2.6   AstraZeneca

20.2.7   Janssen Pharmaceuticals

 

21         Key Company Profiles

21.1      F. Hoffmann-La Roche

21.1.1   Business Overview

21.1.2   Product Offerings

21.1.3   Key Strategies

21.1.4   Key Strengths

21.1.5   Key Opportunities

21.2      Bristol-Myers Squibb Company

21.2.1   Business Overview

21.2.2   Product Offerings

21.2.3   Key Strategies

21.2.4   Key Strengths

21.2.5   Key Opportunities

21.3      Merck & Co., Inc.

21.3.1   Business Overview

21.3.2   Product Offerings

21.3.3   Key Strategies

21.3.4   Key Strengths

21.3.5   Key Opportunities

21.4      GlaxoSmithKline

21.4.1   Business Overview

21.4.2   Product Offerings

21.4.3   Key Strategies

21.4.4   Key Strengths

21.4.5   Key Opportunities

21.5      Novartis

21.5.1   Business Overview

21.5.2   Product Offerings

21.5.3   Key Strategies

21.5.4   Key Strengths

21.5.5   Key Opportunities

21.6      Astrazeneca

21.6.1   Business Overview

21.6.2   Product Offerings

21.6.3   Key Strategies

21.6.4   Key Strengths

21.6.5   Key Opportunities

21.7      Janssen Pharmaceuticals, Inc.

21.7.1   Business Overview

21.7.2   Product Offerings

21.7.3   Key Strategies

21.7.4   Key Strengths

21.7.5   Key Opportunities

 

22         Other Prominent Vendors

22.1       Abbvie

22.1.1    Business Overview

22.1.2    Product Offerings

22.2       Alexion Pharmaceuticals

22.2.1    Business Overview

22.2.2    Product Offerings

22.3       Amgen

22.3.1    Business Overview

22.3.2    Product Offerings

22.4       Bayer

22.4.1    Business Overview

22.4.2    Product Offerings

22.5       Dendreon

22.5.1    Business Overview

22.5.2    Product Offerings

22.6       Dynavax

22.6.1    Business Overview

22.6.2    Product Offerings

22.7       Eli Lilly & Company

22.7.1    Business Overview

22.7.2    Product Offerings

22.8       Elusys Therapeutics, Inc.

22.8.1    Business Overview

22.8.2    Product Offerings

22.9       Gilead Sciences, Inc.

22.9.1     Business Overview

22.9.2    Product Offerings

22.10     NBE Therapeutics

22.10.1  Business Overview

22.11     Pfizer, Inc.

22.11.1  Business Overview

22.11.2  Product Offerings

22.12     Sanofi

22.12.1  Business Overview

22.12.2  Product Offerings

22.13     Seagen Inc.

22.13.1  Business Overview

22.13.2  Product Offerings

22.14     Teva Pharmaceuticals

22.14.1  Business Overview

22.14.2  Product Offerings

 

23         Report Summary

23.1      Key Takeaways

23.2      Strategic Recommendations

 

24         Quantitative Summary

24.1      Market by Geography

24.2      Market by Product

24.3      Market by Application

 

25         Appendix

25.1      Abbreviations

Exhibit 1             Segmentation of Global Immunotherapy Drugs Market

Exhibit 2             Market Size Calculation Approach 2020

Exhibit 3             Impact of Launch of Next-Generation Immunotherapies

Exhibit 4             Impact of COVID-19 as Growth Catalyst

Exhibit 5             Impact of Investment in R&D Activities

Exhibit 6             Impact of Mergers & Acquisitions

Exhibit 7             Impact of Prevalence of Cancer & Autoimmune Diseases

Exhibit 8             Impact of Approval of Novel Immunotherapy Drugs

Exhibit 9             Impact of Surge in Adoption of CAR T-cell Therapies

Exhibit 10           Number of CAR T-cell Therapies in Clinical Trials (January 2018)

Exhibit 11           Major Vendors Engaged in CAR T-cell Therapy Development

Exhibit 12           Approved CAR T-cell Therapies

Exhibit 13           Impact of Expensive Nature of Immunotherapy

Exhibit 14           Impact of Personalized Approach through Biomarkers

Exhibit 15           Impact of Time-consuming Production Cycle

Exhibit 16           Global Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 17           Five Forces Analysis 2020

Exhibit 18           Incremental Growth by Product Segment 2020 & 2026

Exhibit 19           Global Monoclonal Antibody Market 2020–2026 ($ billion)

Exhibit 20           Global Immunomodulator Market 2020–2026 ($ billion)

Exhibit 21           Global Funding for Development of Cell Therapy 2017–2020 ($ billion)

Exhibit 22           Revenues of Kymriah and Yescarta ($ million)

Exhibit 23           Global CAR T-cell Therapy Market 2020–2026 ($ billion)

Exhibit 24           Global Other Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 25           Incremental Growth by Application Segment 2020 & 2026

Exhibit 26           Number of Products in Clinical Trials in Oncology Application

Exhibit 27           Global Cancer Immunotherapy Drugs Market 2020-2026 ($ billion)

Exhibit 28           Global Autoimmune & Inflammatory Diseases Immunotherapy Drugs Market 2020-2026 ($ billion)

Exhibit 29           Global Other Immunotherapy Applications Market 2020-2026 ($ billion)

Exhibit 30           Incremental Growth by Geography 2020 & 2026

Exhibit 31           New Cancer Cases Reported in North America 2020

Exhibit 32           Market Share of Major Countries in North America

Exhibit 33           North America Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 34           Incremental Growth in North America 2020 & 2026

Exhibit 35           US Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 36           Immunotherapy Drugs Market in Canada 2020–2026 ($ billion)

Exhibit 37           Market Share of Major Countries in Europe

Exhibit 38           Europe Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 39           Incremental Growth in Europe 2020 & 2026

Exhibit 40           Immunotherapy Drugs Market in Germany 2020–2026 ($ billion)

Exhibit 41           Estimated Number of People Living with Cancer by 2030 (million)

Exhibit 42           UK Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 43           Immunotherapy Drugs Market in France 2020–2026 ($ billion)

Exhibit 44           Per Capita Healthcare Expenditure in Italy between 2016 & 2018 ($)

Exhibit 45           Immunotherapy drugs Market in Italy 2020–2026 ($ billion)

Exhibit 46           Immunotherapy Drugs Market in Spain 2020–2026 ($ billion)

Exhibit 47           Market Share of Major Countries in APAC

Exhibit 48           APAC Immunotherapy drugs Market 2020–2026 ($ billion)

Exhibit 49           Incremental Growth in APAC 2020 & 2026

Exhibit 50           Number of new Types of Cancer Cases reported in China (2020)

Exhibit 51           Immunotherapy Drugs Market in China 2020–2026 (billion)

Exhibit 52           Immunotherapy Drugs Market in India 2020–2026 ($ billion)

Exhibit 53           Immunotherapy Drugs Market in Japan 2020–2026 ($ billion)

Exhibit 54           Immunotherapy Drugs Market in Australia 2020–2026 ($ billion)

Exhibit 55           Number of New Types of Cancer Cases Reported in Australia (2020)

Exhibit 56           Number of New Types of Cancers in South Korea (2020)

Exhibit 57           Immunotherapy Drugs Market in South Korea 2020–2026 ($ billion)

Exhibit 58           New Types of Cancer Cases Reported in Latin America (2020)

Exhibit 59           Market Share of Major Countries in Latin America

Exhibit 60           Latin America Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 61           Incremental Growth in Latin America 2020 & 2026

Exhibit 62           Immunotherapy Drugs Market in Brazil 2020–2026 ($ billion)

Exhibit 63           Number of New Types of Cancer Cases Reported in Mexico (2020)

Exhibit 64           Immunotherapy Drugs Market in Mexico 2020–2026 ($ billion)

Exhibit 65           Immunotherapy Drugs Market in Argentina 2020–2026 ($ billion)

Exhibit 66           Market Share of Major countries in MEA

Exhibit 67           MEA Immunotherapy Drugs Market 2020–2026 ($ billion)

Exhibit 68           Incremental Growth in Middle East & Africa 2020 & 2026

Exhibit 69           Cancer Cases in Key Countries across MEA 2020

Exhibit 70           Immunotherapy Drugs Market in South Africa 2020–2026 ($ billion)

Exhibit 71           Immunotherapy Drugs Market in Saudi Arabia 2020–2026 ($ billion)

Exhibit 72           Number of New Cancer Cases Reported in Turkey (2020)

Exhibit 73           Immunotherapy Drugs Market in Turkey 2020–2026 ($ billion)

Exhibit 74           Global Immunotherapy Drugs Market by Product 2020–2026

Exhibit 75           Global Immunotherapy Drugs Market by Application 2020–2026  
          

LIST OF TABLES       

Table 1               Key Caveats

Table 2               Currency Conversion 2013–2020

Table 3               Major Mergers & Acquisitions

Table 4               Major Approved Immunotherapy Drugs

Table 5               CAR T-cell Investigational Products

Table 6               Cost of Kymriah in Different Regions

Table 7               CAGR & Revenue of Approved CAR T-cell Therapies 2018–2020 ($ million)

Table 8               CAGR & Revenue of Other Approved Therapies 2018–2020 ($ million)

Table 9               CAR-T Therapies Approved in Japan Region

Table 10             F. Hoffmann-La Roche: Major Product Offerings

Table 11             Bristol Myers Squibb: Major Product Offerings

Table 12             Merck & Co., Inc.: Major Product Offerings

Table 13             GlaxoSmithKline: Major Product Offerings

Table 14             Novartis: Major Product Offerings

Table 15             AstraZeneca: Major Product Offerings

Table 16             Janssen Pharmaceuticals, Inc.: Major Product Offerings

Table 17             AbbVie: Major Product Offerings

Table 18             Alexion Pharmaceuticals: Major Product Offerings

Table 19             Amgen: Major Product Offerings

Table 20             Bayer: Major Product Offerings

Table 21             Dendreon: Major Product Offerings

Table 22             Dynavax: Major Product Offerings

Table 23             Eli Lilly & Company: Major Product Offerings

Table 24             Elusys Therapeutics, Inc.: Major Product Offerings

Table 25             Gilead Sciences, Inc.: Major Product Offerings

Table 26             Pfizer, Inc.: Major Product Offerings

Table 27             Sanofi: Major Product Offerings

Table 28             Seagen Inc.: Major Product Offerings

Table 29             Teva Pharmaceuticals: Major Product Offerings

Table 30             Global Immunotherapy Drugs Market by 2020–2026 ($ billion) (Geography)

Table 31             North America Immunotherapy Drugs Market 2020–2026 (%)

Table 32             Europe Immunotherapy Drugs Market 2020–2026 (%)

Table 33             APAC Immunotherapy Drugs Market 2020–2026 (%)

Table 34             Latin America Immunotherapy Drugs Market 2020–2026 (%)

Table 35             MEA Immunotherapy Drugs Market 2020–2026 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3375.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3825.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4725.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1350.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

10%

Off

OFF

DAYS

HOURS

MINUTES

SECONDS

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date